

2007-2008 ACG Board of Trustees Disclosure Declaration

It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. The Accreditation Council for Continuing Medical Education requires CME providers to demonstrate that everyone who is in a position to control the content of an education activity has disclosed all relevant financial relationships with any commercial interest to the provider. Oversight of all educational programming content is conducted by the ACG Board of Trustees through a review and approval process. Board of Trustees members have noted the following relationships.

President

Amy E. Foxx-Orenstein, D.O., FACP, Rochester, MN
Advisory Board: Novartis

President-Elect

Eamonn M.M. Quigley, M.D., FACP, Cork, Ireland
Director/Stockholder: Alimentary Health
Consultant: AGI Therapeutics
Advisory Board: Boehringer Ingelheim, GlaxoSmithKline
Research funding: Procter & Gamble, Pfizer, AGI, GlaxoSmithKline

Vice President

Philip O. Katz, M.D., FACP, Philadelphia, PA
Honoraria for lectures: AstraZeneca, Santarus, TAP
Consultant: AstraZeneca, Horizon Therapeutics, Prometheus, TAP

Treasurer

Delbert L. Chumley, M.D., FACP, San Antonio, TX
Dr. Chumley has indicated no relevant financial relationships.

Secretary

Ronald J. Vender, M.D., FACP, Hamden, CT
Medical Advisory Board: ReShape

Immediate Past President

David A. Johnson, M.D., FACP, Norfolk, VA
Research grants: AstraZeneca, TAP, Spirus

Chair, Board of Governors

Francis A. Farraye, M.D., FACP, Boston, MA
Speaker's Bureau: Abbott, Procter & Gamble, Shire, Salix, Prometheus, UCB
Advisory Board: Abbott, UCB, Prometheus

Past President

Jack A. DiPalma, M.D., FACP, Mobile, AL

Consultant/Medical Director: Braintree Laboratories
Research Support: Takeda
Speaker: AstraZeneca
Speaker/Consultant: Given Imaging
Stockholder: Bovie Medical

Director, ACG Institute
Edgar Achkar, M.D., FACP, Cleveland, OH
Dr. Achkar has indicated no relevant financial relationships.

Vice Chair, Board of Governor
Samir A. Shah, M.D., FACP, Providence, RI
Speaker's Bureau: Abbott, Centocor, Procter & Gamble, Prometheus, Takeda

Co-Editor, *American Journal of Gastroenterology*
Joel E. Richter, M.D., MACG, Philadelphia, PA
Honoraria: AstraZeneca, TAP

Co-Editor, *American Journal of Gastroenterology*
Nicholas J. Talley, M.D., PhD., FACP, Jacksonville, FL
Consultant: AccrediEd, Addex Pharmaceuticals, SA, Annanberg Center, Astellas Pharma, Inc. US, AstraZeneca R&D Lund, Axcan Pharma, Callisto Pharmaceuticals, Conexus, Dynogen, F-Network, Ferring Pharmaceuticals, Inc., Interactive Forum, Inc., Lexicon Genetics, Inc., McNeil Consumer, Medscape from WebMD, Metabolic Pharma, MGI Pharma, Microbia, Inc., Novartis, Oakstone Publishing, Optum HC, Procter & Gamble, Salix
Financial Support: Novartis, Takeda, GlaxoSmithKline, Dynogen, Tioga

Editor, *Nature*
Stephen B. Hanauer, M.D., FACP, Chicago, IL
Consultant: Abbott Labs, Elan/Biogen, Centocor, UCB, Shire, Prometheus, Procter & Gamble, Axcan, AstraZeneca, McNeil, GlaxoSmithKline

Trustees:
Carol A. Burke, M.D., FACP, Cleveland, OH
Research Support: Pfizer
Honoraria: Salix, Novartis, Takeda, Lilly (spouse)

Edward L. Cattau, Jr., M.D., FACP, Germantown, TN
Dr. Cattau has indicated no relevant financial relationships.

Anthony N. Kalloo, M.D., FACP, Baltimore, MD
Consultant/Founding Member/Equity Holder: Apollo Endosurgery

Sunanda V. Kane, M.D., MSPH, FACP, Rochester, MN
Research: UCB, Abbott, Shire, Procter & Gamble

*Consultant/Advisory Board: UCB, Abbott, Procter & Gamble, Elan, Shire
Honoraria: Procter & Gamble, Prometheus, Abbott*

W. Elwyn Lyles, M.D., FACG, Alexandria, LA
Dr. Lyles has indicated no relevant financial relationships.

Irving M. Pike, M.D., FACG, Virginia Beach, VA
Stock: Validare

Harry E. Sarles, Jr., M.D., FACG, Garland, TX
Dr. Sarles has indicated no relevant financial relationships.

Lawrence R. Schiller, M.D., FACG, Dallas, TX
Consultant: Novartis, Takeda

Mitchell L. Shiffman, M.D., FACG, Richmond, VA
*Stock Options: Exallence
Grants for Clinical Research: Roche, Schering-Plough, Vertex, Human Genome
Sciences, Gilead, Bristol-Myers Squibb, Valeant, Wyeth*

Roy K.H. Wong, M.D., FACG, Washington, DC
Dr. Wong has indicated no relevant financial relationships.